XML 49 R36.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS (Tables)
6 Months Ended
Jun. 30, 2025
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS  
Schedule of condensed consolidating balance sheet

 

 

Yubo International Biotech Limited (Parent Company)

 

 

Platinum (Cayman Island) and Platinum HK

(Cayman Island)

 

 

Yubo

Global

 

 

Yubo Chengdu

(WFOE)

 

 

Yubo Beijing (VIE

Subsidiaries)

 

 

Elimination

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

$—

 

 

$359

 

 

$77,189

 

 

$—

 

 

$583,747

 

 

$(2,193)

 

$659,102

 

Investment in subsidiaries and variable interest entity (VIE)

 

 

(2,181,987)

 

 

930,000

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,251,987

 

 

 

—

 

Intercompany receivables

 

 

—

 

 

 

—

 

 

 

436,661

 

 

 

—

 

 

 

646,873

 

 

 

(1,083,534)

 

 

—

 

Other assets

 

 

—

 

 

 

—

 

 

 

21,531

 

 

 

—

 

 

 

866,105

 

 

 

(495,171)

 

 

392,465

 

Total Assets

 

$(2,181,987)

 

$930,359

 

 

 

535,381

 

 

 

—

 

 

 

2,096,725

 

 

 

(328,911)

 

 

1,051,567

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

$—

 

 

$150,000

 

 

$77,854

 

 

$—

 

 

$4,797,616

 

 

$—

 

 

$5,025,470

 

Intercompany payables

 

 

—

 

 

 

—

 

 

 

43,969

 

 

 

—

 

 

 

1,039,565

 

 

 

(1,083,534)

 

 

—

 

Other liabilities

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

7,812

 

 

 

—

 

 

 

7,812

 

 Total Liabilities

 

 

—

 

 

 

150,000

 

 

 

121,823

 

 

 

—

 

 

 

5,844,993

 

 

 

(1,083,534)

 

 

5,033,282

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders' Deficit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital stock and additional paid in capital

 

 

—

 

 

 

1,569,229

 

 

 

835,513

 

 

 

—

 

 

 

2,163,147

 

 

 

(1,458,586)

 

 

3,109,303

 

Accumulated deficit

 

 

(2,181,987)

 

 

(788,870)

 

 

(421,955)

 

 

—

 

 

 

(5,911,415)

 

 

1,959,667

 

 

 

(7,344,560)

Accumulated other comprehensive income (loss)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

 

 

 

 

235,013

 

 

 

235,013

 

Non—controlling interests

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

18,529

 

 

 

18,529

 

Total Deficit

 

 

(2,181,987)

 

 

780,359

 

 

 

413,558

 

 

 

—

 

 

 

(3,748,268)

 

 

756,817

 

 

 

(3,981,715)

Total Liabilities and Shareholders' Equity

 

$(2,181,987)

 

$930,359

 

 

$535,381

 

 

$—

 

 

$2,096,725

 

 

$(328,911)

 

$1,051,567

 

Schedule of condensed consolidating statement of operations

 

 

Yubo International Biotech Limited (Parent Company)

 

 

Platinum (Cayman Island) and Platinum HK

(Cayman Island)

 

 

Yubo

Global

 

 

Yubo Chengdu

(WFOE)

 

 

Yubo Beijing (VIE

Subsidiaries)

 

 

Elimination

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales of product and services

 

$—

 

 

$—

 

 

$—

 

 

$—

 

 

$—

 

 

$—

 

 

$—

 

Cost of goods and services sold

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Gross profit

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Total operating expenses

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

592,094

 

 

 

—

 

 

 

592,094

 

Loss from operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(592,094)

 

 

—

 

 

 

(592,094)

Other income (expense)

 

 

—

 

 

 

—

 

 

 

(2)

 

 

—

 

 

 

(40)

 

 

—

 

 

 

(42)

Equity in net loss of subsidiaries and variable interest entity (VIE)

 

 

(1,628,906)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,628,906

 

 

 

—

 

Net Loss

 

$(1,628,906)

 

$—

 

 

$(2)

 

$—

 

 

$(592,134)

 

$1,628,906

 

 

$(592,136)